The complement proteins C3 and protease factor B have a central role in the activation pathways of the complement system. Recent advances in the structural biology of complement protein C3 ...

Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5mFunds will be used to further develop ...

These PK/PD data support the selection of 8mg/kg as the optimal dose for intravenous administration every 8 weeks to achieve complete suppression (> 98 percent) of alternative pathway activation ...